达罗他胺对比阿帕他胺与恩扎卢胺治疗非转移性去势抵抗性前列腺癌的间接比较
本研究通过匹配调整间接比较,利用ARAMIS试验个体数据重新加权以匹配SPARTAN和PROSPER试验的入组标准与基线特征,比较达罗他胺与阿帕他胺或恩扎卢胺在非转移性去势抵抗性前列腺癌中的预设不良事件和无转移生存。匹配后无转移生存风险比无差异,但达罗他胺相比阿帕他胺跌倒、骨折和皮疹发生率显著更低,相比恩扎卢胺跌倒、头晕、精神损害、疲劳和严重疲劳发生率显著更低。
要点
- 匹配后达罗他胺与阿帕他胺或恩扎卢胺的无转移生存风险比无差异
- 达罗他胺相比阿帕他胺跌倒、骨折和皮疹发生率显著更低
- 达罗他胺相比恩扎卢胺跌倒、头晕、精神损害、疲劳和严重疲劳发生率显著更低
核心结论
- 匹配调整间接比较显示达罗他胺与阿帕他胺或恩扎卢胺在无转移生存上无差异,但达罗他胺在预设不良事件上安全性更优。
研究设计与样本
- 匹配调整间接比较,利用ARAMIS试验个体患者数据(安慰剂553例,达罗他胺943例)重新加权匹配SPARTAN(安慰剂401例,阿帕他胺806例)和PROSPER(安慰剂468例,恩扎卢胺933例)的入组标准与基线特征。
主要发现
- 匹配后达罗他胺对比阿帕他胺和达罗他胺对比恩扎卢胺的无转移生存风险比均无差异。
- 达罗他胺对比阿帕他胺:跌倒、骨折和皮疹发生率显著更低。
- 达罗他胺对比恩扎卢胺:跌倒、头晕、精神损害、疲劳和严重疲劳发生率显著更低。
关键数值与推荐
- 两项间接比较均匹配年龄、前列腺特异性抗原水平及倍增时间、东部肿瘤协作组体能状态、Gleason评分和骨保护剂使用。
- 达罗他胺对比阿帕他胺额外匹配既往手术,达罗他胺对比恩扎卢胺额外匹配地区。
临床怎么用
- 在非转移性去势抵抗性前列腺癌的临床决策和治疗选择中应考虑这些不良事件差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: No published head-to-head randomized trials have compared the safety and efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration-resistant prostate cancer. This study compares prespecified adverse events and metastasis-free survival associated with darolutamide vs apalutamide, and darolutamide vs enzalutamide, via matching-adjusted indirect comparisons. MATERIALS AND METHODS: Individual patient data from the phase III ARAMIS trial (NPLACEBO=553; NDAROLUTAMIDE=943) were selected and reweighted to match the inclusion criteria and baseline characteristics published for the phase III SPARTAN (NPLACEBO=401; NAPALUTAMIDE=806) and PROSPER (NPLACEBO=468; NENZALUTAMIDE=933) trials. Only baseline factors consistently reported across trials were included as matching covariates. Both indirect comparisons matched on age, prostate specific antigen level and doubling time, Eastern Cooperative Oncology Group performance status, Gleason score, and bone-sparing agent use. Darolutamide vs apalutamide also matched on prior surgery and darolutamide vs enzalutamide also matched on region. Risk differences and odds ratios were calculated for adverse events and hazard ratios for metastasis-free survival. RESULTS: No differences in metastasis-free survival hazard ratios were found after matching in either comparison. However, fall, fracture and rash rates were statistically significantly lower in favor of darolutamide vs apalutamide. Fall, dizziness, mental impairment, fatigue and severe fatigue rates were statistically significantly lower in favor of darolutamide vs enzalutamide. CONCLUSIONS: While metastasis-free survival did not differ across drugs in these cross-trial indirect comparisons, darolutamide showed a favorable safety and tolerability profile in prespecified adverse events vs apalutamide and enzalutamide. Consideration of these adverse events is important in clinical decision-making and treatment selection in nonmetastatic castration-resistant prostate cancer.
引用
- Halabi S, Jiang S, Terasawa E, et al. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. J Urol. 2021. PMID: 33818140. doi:10.1097/JU.0000000000001767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。